Severe Uncontrolled Asthma
Internal Medicine Studies
INDICATION
AGE CRITERIA
DESCRIPTION
18 – 75, inclusive
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment (ANDHI)
Uncontrolled Asthma
≥12 years
A 12-week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma
Chronic Cough
≥ 18 yrs. old
A Phase 3, Randomized, Double-blind, Placebo-controlled, 12-month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027)
Concussion/OI
15-17
Saliva biomarkers for noninvasive diagnostics of acute mTBI in children
Chronic Cough
18-80, inclusive
A Dose Escalation Study to Assess the Efficacy and Safety of Bradanicline in Subjects with Refractory Chronic Cough